16th May 2014 12:23
LONDON (Alliance News) - Tissue Regenix Group PLC said Friday that it had won a US patent to cover the use of its dCELL technology for tissue implants for bladder repair.
Tissue Regenix's dCELL decellularisation process removes DNA and other cellular material from animal and human tissue leaving an acellular tissue scaffold, which can then be used to repair diseased or worn-out body parts.
The new patent, follows on from a patent won to cover the use of its dCELL technology for mensical implants in China, last month, to repair knee injuries. Mensical implants are used to replace the menisci, the cartilage that acts as a shock absorber in the knee joint.
"This latest patent adds to our fast-growing global portfolio, and will allow Tissue Regenix to use our dCELL technology to help treat an array of urinary diseases and conditions in North America," said Chief Executive Anthony Odell in a statement.
Shares in the regenerative medical devices company were flat Friday afternoon at 24.50 pence.
By Rowena Harris-Doughty; [email protected]; @rharrisdoughty
Copyright 2014 Alliance News Limited. All Rights Reserved.
Related Shares:
Tissue Regenix Group